| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10342791 | 60 DEGREES PHARMS | Regimens of tafenoquine for prevention of malaria in malaria-naive subjects |
Dec, 2035
(12 years from now) | |
| US10888558 | 60 DEGREES PHARMS | Regimens of tafenoquine for prevention of malaria in malaria-naive subjects |
Dec, 2035
(12 years from now) | |
| US11744828 | 60 DEGREES PHARMS | Regimens of tafenoquine for prevention of malaria in malaria-naïve subjects |
Dec, 2035
(12 years from now) | |
Arakoda is owned by 60 Degrees Pharms.
Arakoda contains Tafenoquine Succinate.
Arakoda has a total of 3 drug patents out of which 0 drug patents have expired.
Arakoda was authorised for market use on 08 August, 2018.
Arakoda is available in tablet;oral dosage forms.
Arakoda can be used as for the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose.
Drug patent challenges can be filed against Arakoda from 2022-07-20.
The generics of Arakoda are possible to be released after 02 December, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 20, 2023 |
Drugs and Companies using TAFENOQUINE SUCCINATE ingredient
NCE-1 date: 2022-07-20
Market Authorisation Date: 08 August, 2018
Treatment: For the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose
Dosage: TABLET;ORAL
ARAKODA family patents
